logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer Says Xarelto Proven Effective In Treating Patients With Pulmonary Embolism

Bayer HealthCare, a subgroup of Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the oral anticoagulant Xarelto, or rivaroxaban, used as a single drug intervention, was as effective and safe as the current dual drug approach of subcutaneous enoxaparin followed by Vitamin K antagonist, in treating patients with acute symptomatic pulmonary embolism and preventing them from developing a secondary venous blood clot.

Rivaroxaban showed similar overall bleeding rates, but was associated with significantly lower rates of major bleeding versus the current standard of care.

The company noted that Rivaroxaban was also proven effective in preventing recurrent venous blood clots in Phase III EINSTEIN-PE Study.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Computer and printer maker Hewlett-Packard Co. said Thursday after the markets closed that its second quarter profit fell 21% from last year, hurt by lower revenue and costs related to the planned separation of the company. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Accounting software maker Intuit reported a plunge in third-quarter profit, hurt by impairment charges, even as results topped Wall Street estimates, driven by growth in small business segment amid a strong tax season. Struggling teen-apparel retailer Aeropostale Inc. (ARO), Thursday said its first-quarter loss narrowed from a year ago, driven largely by stronger margins even as revenues continued to plunge dropped. Nevertheless, the company lost almost one-fifth of its market value in after-hours trade, with the...
comments powered by Disqus
Follow RTT